Aldeyra Stock Today
| ALDX Stock | USD 4.84 0.06 1.26% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Aldeyra is trading at 4.84 as of the 18th of January 2025; that is 1.26 percent increase since the beginning of the trading day. The stock's open price was 4.78. Aldeyra has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 29th of January 2023 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of May 2014 | Category Healthcare | Classification Health Care |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. Aldeyra Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 59.55 M outstanding shares of which 3.84 M shares are presently shorted by private and institutional investors with about 8.8 trading days to cover. More on Aldeyra
Moving together with Aldeyra Stock
Moving against Aldeyra Stock
Aldeyra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Stephen Machatha | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsAldeyra can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aldeyra's financial leverage. It provides some insight into what part of Aldeyra's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Aldeyra (ALDX) is traded on NASDAQ Exchange in USA. It is located in 131 Hartwell Avenue, Lexington, MA, United States, 02421 and employs 9 people. Aldeyra is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 299.24 M. Aldeyra conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.55 M outstanding shares of which 3.84 M shares are presently shorted by private and institutional investors with about 8.8 trading days to cover.
Aldeyra currently holds about 163.83 M in cash with (30.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8.
Check Aldeyra Probability Of Bankruptcy
Ownership AllocationAldeyra holds a total of 59.55 Million outstanding shares. Over half of Aldeyra's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aldeyra Ownership Details
Aldeyra Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 520.6 K | |
| Ardsley Advisory Partners | 2024-09-30 | 500 K | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 476.9 K | |
| Northern Trust Corp | 2024-09-30 | 388.6 K | |
| Pfg Investments, Llc | 2024-09-30 | 386.4 K | |
| Wells Fargo & Co | 2024-09-30 | 386.3 K | |
| Bank Of America Corp | 2024-09-30 | 375.4 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 334.8 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 302.2 K | |
| Perceptive Advisors Llc | 2024-09-30 | 9.3 M | |
| Knoll Capital Management Lp | 2024-09-30 | 5.5 M |
Aldeyra Historical Income Statement
Aldeyra Stock Against Markets
Aldeyra Corporate Management
| David Burke | Head Relations | Profile | |
| Michael Alfieri | Principal Officer | Profile | |
| Kelly Mizer | Vice Operations | Profile | |
| Laura Nichols | Operations Manager | Profile |
Already Invested in Aldeyra?
The danger of trading Aldeyra is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aldeyra is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aldeyra. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aldeyra is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aldeyra Stock Analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.